<i>ERBB2 and PTPN2 g</i>ene copy numbers as prognostic factors in HER2-positive metastatic breast cancer treated with trastuzumab.

Oncol Lett · 2019 · PMC6396168 · PMID 30867772

Europe PMC DOI

hedged sentence

0.0710

closest p · 1.4× alpha

0.0710

boldest claim

The sentences

showed a trendP=0.071so close (0.05 < p ≤ 0.1)

second or later line of trastuzumab showed a trend towards improved PFS (HR=0.57; 95% CI: 0.31–1.05, P=0.071).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.